FilingReader Intelligence
Sino Biopharmaceutical gets China approval for novel cancer drug trial
August 11, 2025 at 05:00 PM UTC•By FilingReader AI
Sino Biopharmaceutical Limited received approval from China's National Medical Products Administration to begin trials of TQB3122, a PARP1 inhibitor for advanced malignant tumors.
The drug offers strong blood-brain barrier penetration and targets tumor cells with BRCA mutations. No drugs with the same target are currently approved globally.
The company will test TQB3122's safety and efficacy in advanced solid tumors, particularly intracranial tumors.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1177•Hong Kong Exchange
News Alerts
Get instant email alerts when Sino Biopharmaceutical publishes news
Free account required • Unsubscribe anytime